Search Femetric

Search peptides, goals, protocols and references

Weight ManagementGlucose / InsulinFat LossBody Composition

RESEARCH REFERENCE

Mazdutide

A GLP-1 and glucagon receptor dual agonist studied in obesity and type 2 diabetes, with development and regulatory status varying by region.

02

How this works

Mazdutide is an oxyntomodulin-derived dual GLP-1 and glucagon receptor agonist. Femetric date-stamps regional development and approval context rather than assuming one global status.

03

Benefits + side effects

Potential Benefits

  • Weight Management
  • Glucose / Insulin
  • Fat Loss
  • Body Composition
10

References

01
Efficacy and Safety of Mazdutide in Chinese Patients With Overweight or ObesityDiabetes Care · 2023
CLINICAL TRIAL

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.
By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.
NEXT RESEARCH ACTION
Was this useful?